PT - JOURNAL ARTICLE AU - Kateřina Sikorová AU - Veronika Zizková AU - Lenka Kocourková AU - Adam Strnad AU - Martina Doubková AU - Martin Petrek AU - Martin Petřek TI - HLA Associations in Czech Patients with Sarcoidosis AID - 10.1183/13993003.congress-2021.PA702 DP - 2021 Sep 05 TA - European Respiratory Journal PG - PA702 VI - 58 IP - suppl 65 4099 - http://erj.ersjournals.com/content/58/suppl_65/PA702.short 4100 - http://erj.ersjournals.com/content/58/suppl_65/PA702.full SO - Eur Respir J2021 Sep 05; 58 AB - Objective: Sarcoidosis is immune-mediated disease, in the pathogenesis of which polymorphic genes of the immune system are involved. We have used next-generation sequencing (NGS) allowing detailed characterisation of HLA alleles to investigate the role of HLA variation in sarcoidosis.Methods: We enrolled 248 patients diagnosed by ATS/ERS/WASOG guidelines at Brno University Hospital. We performed genotyping of 7 HLA loci (HLA-A, -B, -C, -DRB1, -DQA1, -DQB1, -DPB1) by Omixon Holotype™ kit and HLATwin software™.  HLA allele frequency was compared with data of HLA polymorphism distribution in the same loci with the same resolution typing by NGS in 168 unrelated Czech subjects. For the current analysis, 4 digit characteristics of HLA genotyping results were used. Associations were assessed by two-tailed Fischer’s exact test and Bonferroni correction for multiple comparisons.Results: Tab.1 shows 7 variants associated with sarcoidosis as a whole and Tab.2 illustrates 5 variants associated with Lofgren syndrome (LS).Conclusion: We document some previously described associations between sarcoidosis and HLA such as those in HLA-DQB1*06 and HLA-B*08 and, further suggest some novel. In future we plan to extend the work into dissecting relationships of HLA and clinical course, here indicated by LS association. HLAOdds ratiopcorrB*08:012.240.03C*07:011.940.03DQA1*01:022.134.65*10-4DQB1*03:010.460.03DQB1*03:020.179.31*10-4DQB1*06:022.265.34*10-3DQB1*06:046.700.03Tab.1: Variants associated with sarcoidosis (Odds ratio>1.0, risk; <1.0, protective)HLApcorrDQA1*05:011.79*10-7DRB1*03:016.35*10-6C*07:012.96*10-4B*08:011.81*10-3A*01:010.01Tab. 2: Variants associated with LSFunding: NV18-05-00134, IGAUP:LF2021_014FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA702.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).